$SNDX
Syndax Pharmaceuticals Inc

2020 Q1 Form 10-Q Financial Statement

#000156459020022971 Filed on May 07, 2020

View on sec.gov

Income Statement

Concept 2020 Q1 2019 Q1
Revenue $379.0K $379.0K
YoY Change 0.0% 0.0%
Cost Of Revenue
YoY Change
Gross Profit
YoY Change
Gross Profit Margin
Selling, General & Admin $5.920M $3.910M
YoY Change 51.41% -18.37%
% of Gross Profit
Research & Development $9.562M $11.28M
YoY Change -15.22% -26.47%
% of Gross Profit
Depreciation & Amortization $20.00K
YoY Change
% of Gross Profit
Operating Expenses $15.48M $15.19M
YoY Change 1.9% -24.54%
Operating Profit -$15.10M -$14.81M
YoY Change 1.95% -25.01%
Interest Expense $449.0K $452.0K
YoY Change -0.66% -4.84%
% of Operating Profit
Other Income/Expense, Net -$136.0K $509.0K
YoY Change -126.72% 44.19%
Pretax Income -$15.24M -$14.30M
YoY Change 6.57% -26.29%
Income Tax
% Of Pretax Income
Net Earnings -$15.24M -$14.30M
YoY Change 6.53% -26.27%
Net Earnings / Revenue -4020.05% -3773.61%
Basic Earnings Per Share
Diluted Earnings Per Share -$443.9K -$529.2K
COMMON SHARES
Basic Shares Outstanding 25.00M
Diluted Shares Outstanding

Balance Sheet

Concept 2020 Q1 2019 Q1
SHORT-TERM ASSETS
Cash & Short-Term Investments $101.3M $95.40M
YoY Change 6.18% -16.32%
Cash & Equivalents $44.74M $58.33M
Short-Term Investments $56.70M $37.30M
Other Short-Term Assets $2.600M $2.000M
YoY Change 30.0% -60.0%
Inventory
Prepaid Expenses
Receivables
Other Receivables
Total Short-Term Assets $104.2M $97.60M
YoY Change 6.77% -18.19%
LONG-TERM ASSETS
Property, Plant & Equipment $259.0K $350.0K
YoY Change -26.0% -12.5%
Goodwill
YoY Change
Intangibles
YoY Change
Long-Term Investments
YoY Change
Other Assets $100.0K $200.0K
YoY Change -50.0% 0.0%
Total Long-Term Assets $994.0K $1.800M
YoY Change -44.78% 157.14%
TOTAL ASSETS
Total Short-Term Assets $104.2M $97.60M
Total Long-Term Assets $994.0K $1.800M
Total Assets $105.2M $99.40M
YoY Change 5.84% -17.17%
SHORT-TERM LIABILITIES
YoY Change
Accounts Payable $9.000M $4.400M
YoY Change 104.55% 69.23%
Accrued Expenses $8.300M $9.800M
YoY Change -15.31% -23.44%
Deferred Revenue
YoY Change
Short-Term Debt $0.00 $0.00
YoY Change
Long-Term Debt Due
YoY Change
Total Short-Term Liabilities $18.80M $15.70M
YoY Change 19.75% -7.1%
LONG-TERM LIABILITIES
Long-Term Debt $19.80M $0.00
YoY Change
Other Long-Term Liabilities $13.10M $15.10M
YoY Change -13.25% -6.21%
Total Long-Term Liabilities $32.90M $15.10M
YoY Change 117.88% -6.21%
TOTAL LIABILITIES
Total Short-Term Liabilities $18.80M $15.70M
Total Long-Term Liabilities $32.90M $15.10M
Total Liabilities $51.60M $30.80M
YoY Change 67.53% -6.67%
SHAREHOLDERS EQUITY
Retained Earnings
YoY Change
Common Stock
YoY Change
Preferred Stock
YoY Change
Treasury Stock (at cost)
YoY Change
Treasury Stock Shares
Shareholders Equity $53.51M $68.63M
YoY Change
Total Liabilities & Shareholders Equity $105.2M $99.40M
YoY Change 5.84% -17.17%

Cashflow Statement

Concept 2020 Q1 2019 Q1
OPERATING ACTIVITIES
Net Income -$15.24M -$14.30M
YoY Change 6.53% -26.27%
Depreciation, Depletion And Amortization $20.00K
YoY Change
Cash From Operating Activities -$15.93M -$16.83M
YoY Change -5.38% -15.29%
INVESTING ACTIVITIES
Capital Expenditures $0.00
YoY Change -100.0%
Acquisitions
YoY Change
Other Investing Activities -$19.05M $12.75M
YoY Change -249.41% -0.55%
Cash From Investing Activities -$19.05M $12.75M
YoY Change -249.41% 0.85%
FINANCING ACTIVITIES
Cash Dividend Paid
YoY Change
Common Stock Issuance & Retirement, Net
YoY Change
Debt Paid & Issued, Net
YoY Change
Cash From Financing Activities 55.00M 28.43M
YoY Change 93.48% 86039.39%
NET CHANGE
Cash From Operating Activities -15.93M -16.83M
Cash From Investing Activities -19.05M 12.75M
Cash From Financing Activities 55.00M 28.43M
Net Change In Cash 20.02M 24.35M
YoY Change -17.77% -438.48%
FREE CASH FLOW
Cash From Operating Activities -$15.93M -$16.83M
Capital Expenditures $0.00
Free Cash Flow -$16.83M
YoY Change -16.03%

Facts In Submission

Frame Concept Type Concept / XBRL Key Value Unit
CY2020Q1 dei City Area Code
CityAreaCode
781
CY2020Q1 dei Local Phone Number
LocalPhoneNumber
419-1400
CY2020Q1 dei Entity Filer Category
EntityFilerCategory
Accelerated Filer
CY2019Q4 us-gaap Preferred Stock Value
PreferredStockValue
CY2020Q1 dei Entity Address State Or Province
EntityAddressStateOrProvince
MA
CY2020Q1 dei Entity Incorporation State Country Code
EntityIncorporationStateCountryCode
DE
CY2020Q1 dei Entity Address Address Line1
EntityAddressAddressLine1
35 Gatehouse Drive
CY2020Q1 dei Entity Address Address Line2
EntityAddressAddressLine2
Building D
CY2020Q1 dei Entity Tax Identification Number
EntityTaxIdentificationNumber
32-0162505
CY2020Q1 dei Entity Address Address Line3
EntityAddressAddressLine3
Floor 3
CY2020Q1 dei Entity Address City Or Town
EntityAddressCityOrTown
Waltham
CY2020Q1 dei Entity Address Postal Zip Code
EntityAddressPostalZipCode
02451
CY2019Q4 us-gaap Commitments And Contingencies
CommitmentsAndContingencies
CY2020Q1 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
100000000
CY2020Q1 us-gaap Common Stock Shares Outstanding
CommonStockSharesOutstanding
30240838
CY2020Q1 us-gaap Operating Lease Liability Noncurrent
OperatingLeaseLiabilityNoncurrent
306000
CY2020Q1 us-gaap Preferred Stock Shares Outstanding
PreferredStockSharesOutstanding
0
CY2020Q1 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.0001
CY2020Q1 us-gaap Preferred Stock Shares Authorized
PreferredStockSharesAuthorized
10000000
CY2019Q4 us-gaap Common Stock Shares Outstanding
CommonStockSharesOutstanding
27140484
CY2019Q1 us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
11279000
CY2019Q1 us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
3911000
CY2019Q4 us-gaap Operating Lease Liability Current
OperatingLeaseLiabilityCurrent
478000
CY2020Q1 us-gaap Operating Lease Right Of Use Asset
OperatingLeaseRightOfUseAsset
608000
CY2020Q1 dei Document Transition Report
DocumentTransitionReport
false
CY2020Q1 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
259000
CY2020Q1 us-gaap Prepaid Expense And Other Assets Current
PrepaidExpenseAndOtherAssetsCurrent
5086000
CY2020Q1 us-gaap Assets Current
AssetsCurrent
104206000
CY2020Q1 dei Entity File Number
EntityFileNumber
001-37708
CY2020Q1 dei Current Fiscal Year End Date
CurrentFiscalYearEndDate
--12-31
CY2020Q1 dei Document Quarterly Report
DocumentQuarterlyReport
true
CY2020Q1 us-gaap Short Term Investments
ShortTermInvestments
54376000
CY2020Q1 us-gaap Long Term Loans Payable
LongTermLoansPayable
19792000
CY2019Q1 us-gaap Other Nonoperating Income Expense
OtherNonoperatingIncomeExpense
57000
CY2020Q1 us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
9562000
CY2020Q1 us-gaap Common Stock Shares Issued
CommonStockSharesIssued
30240838
CY2019Q1 us-gaap Net Income Loss
NetIncomeLoss
-14302000
CY2020Q1 us-gaap Operating Income Loss
OperatingIncomeLoss
-15100000
CY2020Q1 us-gaap Interest Expense
InterestExpense
449000
CY2020Q1 us-gaap Investment Income Interest
InvestmentIncomeInterest
333000
CY2019Q1 us-gaap Investment Income Interest
InvestmentIncomeInterest
452000
CY2020Q1 us-gaap Other Nonoperating Income Expense
OtherNonoperatingIncomeExpense
-20000
CY2020Q1 us-gaap Nonoperating Income Expense
NonoperatingIncomeExpense
-136000
CY2019Q1 us-gaap Nonoperating Income Expense
NonoperatingIncomeExpense
509000
CY2020Q1 us-gaap Net Income Loss
NetIncomeLoss
-15236000
CY2020Q1 us-gaap Accretion Amortization Of Discounts And Premiums Investments
AccretionAmortizationOfDiscountsAndPremiumsInvestments
110000
CY2019Q1 us-gaap Net Income Loss Available To Common Stockholders Basic
NetIncomeLossAvailableToCommonStockholdersBasic
-14302000
CY2020Q1 us-gaap Earnings Per Share Basic And Diluted
EarningsPerShareBasicAndDiluted
-0.56
CY2020Q1 us-gaap Net Income Loss Available To Common Stockholders Basic
NetIncomeLossAvailableToCommonStockholdersBasic
-19142000
CY2020Q1 us-gaap Weighted Average Number Of Share Outstanding Basic And Diluted
WeightedAverageNumberOfShareOutstandingBasicAndDiluted
34328640
CY2019Q1 us-gaap Earnings Per Share Basic And Diluted
EarningsPerShareBasicAndDiluted
-0.53
CY2019Q1 us-gaap Weighted Average Number Of Share Outstanding Basic And Diluted
WeightedAverageNumberOfShareOutstandingBasicAndDiluted
27023466
CY2020Q1 us-gaap Profit Loss
ProfitLoss
-15236000
CY2019Q1 us-gaap Profit Loss
ProfitLoss
-14302000
CY2020Q1 sndx Depreciation And Related Adjustment
DepreciationAndRelatedAdjustment
23000
CY2019Q1 sndx Depreciation And Related Adjustment
DepreciationAndRelatedAdjustment
-180000
CY2019Q4 us-gaap Preferred Stock Par Or Stated Value Per Share
PreferredStockParOrStatedValuePerShare
0.001
CY2019Q4 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
100000000
CY2019Q4 us-gaap Preferred Stock Shares Authorized
PreferredStockSharesAuthorized
10000000
CY2019Q4 us-gaap Preferred Stock Shares Outstanding
PreferredStockSharesOutstanding
0
CY2019Q4 us-gaap Common Stock Shares Issued
CommonStockSharesIssued
27140484
CY2019Q4 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.0001
CY2020Q1 us-gaap Net Cash Provided By Used In Financing Activities
NetCashProvidedByUsedInFinancingActivities
54998000
CY2020Q1 us-gaap Proceeds From Stock Plans
ProceedsFromStockPlans
64000
CY2020Q1 us-gaap Proceeds From Stock Options Exercised
ProceedsFromStockOptionsExercised
338000
CY2020Q1 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect
20020000
CY2019Q4 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations
24724000
CY2018Q4 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations
33985000
CY2020Q1 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations
44744000
CY2020Q1 us-gaap Interest Paid Net
InterestPaidNet
126000
CY2020Q1 sndx Noncash Operating Lease Expense
NoncashOperatingLeaseExpense
108000
CY2019Q1 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations
58332000
CY2019Q1 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect
24347000
CY2020Q1 us-gaap Debt Issuance Costs Incurred During Noncash Or Partial Noncash Transaction
DebtIssuanceCostsIncurredDuringNoncashOrPartialNoncashTransaction
82000
CY2019Q1 us-gaap Debt Issuance Costs Incurred During Noncash Or Partial Noncash Transaction
DebtIssuanceCostsIncurredDuringNoncashOrPartialNoncashTransaction
171000
CY2020Q1 us-gaap Paid In Kind Interest
PaidInKindInterest
62000
CY2020Q1 us-gaap Share Based Compensation
ShareBasedCompensation
1829000
CY2019Q1 us-gaap Share Based Compensation
ShareBasedCompensation
1592000
CY2020Q1 us-gaap Increase Decrease In Prepaid Deferred Expense And Other Assets
IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets
2530000
CY2019Q1 us-gaap Increase Decrease In Prepaid Deferred Expense And Other Assets
IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets
2453000
CY2020Q1 us-gaap Increase Decrease In Accounts Payable
IncreaseDecreaseInAccountsPayable
2820000
CY2019Q1 us-gaap Increase Decrease In Accounts Payable
IncreaseDecreaseInAccountsPayable
2908000
CY2020Q1 us-gaap Increase Decrease In Contract With Customer Liability
IncreaseDecreaseInContractWithCustomerLiability
-379000
CY2019Q1 us-gaap Increase Decrease In Contract With Customer Liability
IncreaseDecreaseInContractWithCustomerLiability
-379000
CY2020Q1 us-gaap Increase Decrease In Accrued Liabilities And Other Operating Liabilities
IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities
-2512000
CY2019Q1 us-gaap Increase Decrease In Accrued Liabilities And Other Operating Liabilities
IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities
-4017000
CY2020Q1 us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
-15925000
CY2019Q1 us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
-16831000
CY2020Q1 us-gaap Payments To Acquire Short Term Investments
PaymentsToAcquireShortTermInvestments
34938000
CY2019Q1 us-gaap Payments To Acquire Short Term Investments
PaymentsToAcquireShortTermInvestments
20628000
CY2020Q1 us-gaap Proceeds From Sale And Maturity Of Available For Sale Securities
ProceedsFromSaleAndMaturityOfAvailableForSaleSecurities
15885000
CY2019Q1 us-gaap Proceeds From Sale And Maturity Of Available For Sale Securities
ProceedsFromSaleAndMaturityOfAvailableForSaleSecurities
33380000
CY2020Q1 us-gaap Net Cash Provided By Used In Investing Activities
NetCashProvidedByUsedInInvestingActivities
-19053000
CY2019Q1 us-gaap Net Cash Provided By Used In Investing Activities
NetCashProvidedByUsedInInvestingActivities
12752000
CY2020Q1 us-gaap Proceeds From Debt Net Of Issuance Costs
ProceedsFromDebtNetOfIssuanceCosts
19730000
CY2019Q1 us-gaap Proceeds From Stock Plans
ProceedsFromStockPlans
27000
CY2019Q1 us-gaap Proceeds From Payments For Other Financing Activities
ProceedsFromPaymentsForOtherFinancingActivities
-2000
CY2019Q1 us-gaap Net Cash Provided By Used In Financing Activities
NetCashProvidedByUsedInFinancingActivities
28426000
CY2020Q1 us-gaap Nature Of Operations
NatureOfOperations
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:0%;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">1. Nature of Business </p> <p style="margin-bottom:0pt;margin-top:6pt;text-indent:4.54%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Syndax Pharmaceuticals, Inc. (&#8220;we,&#8221; &#8220;us,&#8221; &#8220;our&#8221; or the &#8220;Company&#8221;) is a clinical stage biopharmaceutical company developing an innovative pipeline of cancer therapies. We were incorporated in Delaware in 2005. We base our operations in Waltham, Massachusetts and we operate in one segment.</p>
CY2020Q1 us-gaap Use Of Estimates
UseOfEstimates
<p style="margin-bottom:0pt;margin-top:6pt;margin-left:4.54%;text-indent:0%;font-style:italic;font-size:10pt;font-family:Times New Roman;font-weight:normal;text-transform:none;font-variant: normal;">Use of Estimates<font style="font-weight:bold;"> </font></p> <p style="margin-bottom:0pt;margin-top:6pt;text-indent:4.54%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The preparation of condensed consolidated financial statements in conformity with U.S. GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and the disclosure of contingent assets and liabilities at the date of the condensed consolidated financial statements and the reported amounts of costs and expenses during the reporting period. The Company bases estimates and assumptions on historical experience when available and on various factors that it believes to be reasonable under the circumstances. The Company evaluates its estimates and assumptions on an ongoing basis. The Company&#8217;s actual results may differ from these estimates under different assumptions or conditions.</p> <p style="margin-bottom:0pt;margin-top:6pt;text-indent:4.54%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">We anticipate that the COVID-19 pandemic will have an impact on the clinical and pre-clinical development timelines for our clinical and pre-clinical programs. Estimates and assumptions about future events and their effects cannot be determined with certainty and therefore require the exercise of judgment. As of the date of issuance of these financial statements, the Company is not aware of any specific event or circumstance that would require the Company to update its estimates, assumptions and judgments or revise the carrying value of its assets or liabilities. These estimates may change as new events occur and additional information is obtained and are recognized in the consolidated financial statements as soon as they become known. Actual results could differ from those estimates and any such differences may be material to the Company&#8217;s financial statements.</p>
CY2019Q4 us-gaap Prepaid Insurance
PrepaidInsurance
214000
CY2020Q1 us-gaap Number Of Operating Segments
NumberOfOperatingSegments
1
CY2020Q1 dei Entity Incorporation Date Of Incorporation
EntityIncorporationDateOfIncorporation
2005-10-11
CY2020Q1 us-gaap Stock Issued During Period Shares New Issues
StockIssuedDuringPeriodSharesNewIssues
2095039
CY2020Q1 us-gaap Stock Issued During Period Shares New Issues
StockIssuedDuringPeriodSharesNewIssues
3036719
CY2020Q1 us-gaap Debt Securities Available For Sale Realized Gain Loss
DebtSecuritiesAvailableForSaleRealizedGainLoss
0
CY2019Q1 us-gaap Debt Securities Available For Sale Realized Gain Loss
DebtSecuritiesAvailableForSaleRealizedGainLoss
0
CY2020Q1 us-gaap Available For Sale Debt Securities Amortized Cost Basis
AvailableForSaleDebtSecuritiesAmortizedCostBasis
54328000
CY2019Q4 us-gaap Available For Sale Debt Securities Amortized Cost Basis
AvailableForSaleDebtSecuritiesAmortizedCostBasis
36336000
CY2020Q1 us-gaap Available For Sale Debt Securities Accumulated Gross Unrealized Gain Before Tax
AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax
86000
CY2019Q4 us-gaap Available For Sale Debt Securities Accumulated Gross Unrealized Gain Before Tax
AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax
5000
CY2020Q1 us-gaap Available For Sale Debt Securities Accumulated Gross Unrealized Loss Before Tax
AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax
38000
CY2019Q4 us-gaap Available For Sale Debt Securities Accumulated Gross Unrealized Loss Before Tax
AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax
5000
CY2020Q1 us-gaap Available For Sale Securities Debt Securities
AvailableForSaleSecuritiesDebtSecurities
54376000
CY2019Q4 us-gaap Available For Sale Securities Debt Securities
AvailableForSaleSecuritiesDebtSecurities
36336000
CY2020Q1 us-gaap Deposits Assets Current
DepositsAssetsCurrent
2343000
CY2019Q4 us-gaap Deposits Assets Current
DepositsAssetsCurrent
1297000
CY2020Q1 us-gaap Supplies
Supplies
152000
CY2019Q4 us-gaap Supplies
Supplies
166000
CY2020Q1 us-gaap Interest Receivable Current
InterestReceivableCurrent
167000
CY2019Q4 us-gaap Interest Receivable Current
InterestReceivableCurrent
116000
CY2020Q1 sndx Reimbursable Costs
ReimbursableCosts
324000
CY2019Q4 sndx Reimbursable Costs
ReimbursableCosts
416000
CY2020Q1 us-gaap Prepaid Insurance
PrepaidInsurance
1693000
CY2020Q1 us-gaap Other Prepaid Expense Current
OtherPrepaidExpenseCurrent
407000
CY2019Q4 us-gaap Other Prepaid Expense Current
OtherPrepaidExpenseCurrent
347000
CY2020Q1 us-gaap Accrued Professional Fees Current
AccruedProfessionalFeesCurrent
373000
CY2019Q4 us-gaap Accrued Professional Fees Current
AccruedProfessionalFeesCurrent
403000
CY2020Q1 us-gaap Employee Related Liabilities Current
EmployeeRelatedLiabilitiesCurrent
1223000
CY2019Q4 us-gaap Employee Related Liabilities Current
EmployeeRelatedLiabilitiesCurrent
2800000
CY2020Q1 sndx Accrued Clinical Costs Current
AccruedClinicalCostsCurrent
5664000
CY2019Q4 sndx Accrued Clinical Costs Current
AccruedClinicalCostsCurrent
6726000
CY2020Q1 us-gaap Other Accrued Liabilities Current
OtherAccruedLiabilitiesCurrent
535000
CY2019Q4 us-gaap Other Accrued Liabilities Current
OtherAccruedLiabilitiesCurrent
266000
CY2020Q1 us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
1829000
CY2019Q1 us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
1592000
CY2020Q1 us-gaap Stock Issued During Period Shares Stock Options Exercised
StockIssuedDuringPeriodSharesStockOptionsExercised
51034
CY2020Q1 us-gaap Warrants And Rights Outstanding Term
WarrantsAndRightsOutstandingTerm
P4M24D
CY2019Q1 sndx Number Of Series Of Warrants
NumberOfSeriesOfWarrants
2
CY2019Q1 sndx Gross Proceeds From Offering
GrossProceedsFromOffering
27600000
CY2019Q1 sndx Offering Cost
OfferingCost
200000
CY2019Q1 us-gaap Warrants And Rights Outstanding Term
WarrantsAndRightsOutstandingTerm
P1Y4M24D
CY2020Q1 sndx Adjustments To Additional Paid In Capital Repricing Warrants
AdjustmentsToAdditionalPaidInCapitalRepricingWarrants
3900000
CY2019Q1 us-gaap Stock Issued During Period Shares Stock Options Exercised
StockIssuedDuringPeriodSharesStockOptionsExercised
0
CY2020Q1 us-gaap Long Term Debt Maturities Repayments Of Principal In Year Two
LongTermDebtMaturitiesRepaymentsOfPrincipalInYearTwo
3057000
CY2020Q1 us-gaap Long Term Debt Maturities Repayments Of Principal In Year Three
LongTermDebtMaturitiesRepaymentsOfPrincipalInYearThree
9809000
CY2020Q1 us-gaap Long Term Debt Maturities Repayments Of Principal In Year Four
LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFour
7134000
CY2020Q1 us-gaap Debt Instrument Carrying Amount
DebtInstrumentCarryingAmount
20000000
CY2020Q1 us-gaap Unamortized Loss Reacquired Debt Noncurrent
UnamortizedLossReacquiredDebtNoncurrent
49000
CY2020Q1 us-gaap Unamortized Debt Issuance Expense
UnamortizedDebtIssuanceExpense
257000
CY2020Q1 us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
1829000
CY2020Q1 sndx Stock Issued During Period Value Direct Offering
StockIssuedDuringPeriodValueDirectOffering
24201000
CY2020Q1 sndx Stock Issued During Period Value Pre Funded Common Stock Warrants From Direct Offering
StockIssuedDuringPeriodValuePreFundedCommonStockWarrantsFromDirectOffering
10665000
CY2020Q1 us-gaap Stock Issued During Period Value Stock Options Exercised
StockIssuedDuringPeriodValueStockOptionsExercised
338000
CY2020Q1 us-gaap Adjustment To Additional Paid In Capital Income Tax Effect From Share Based Compensation Net
AdjustmentToAdditionalPaidInCapitalIncomeTaxEffectFromShareBasedCompensationNet
64000
CY2018Q4 us-gaap Stockholders Equity
StockholdersEquity
53047000
CY2019Q1 sndx Stock Issued During Period Value At The Market Offering Net
StockIssuedDuringPeriodValueAtTheMarketOfferingNet
830000
CY2019Q1 us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
1592000
CY2019Q1 sndx Stock Issued During Period Value Direct Offering
StockIssuedDuringPeriodValueDirectOffering
10922000
CY2019Q1 sndx Stock Issued During Period Value Pre Funded Common Stock Warrants From Direct Offering
StockIssuedDuringPeriodValuePreFundedCommonStockWarrantsFromDirectOffering
13032000
CY2019Q1 sndx Stock Issued During Period Value Common Stock Warrant With Direct Offering
StockIssuedDuringPeriodValueCommonStockWarrantWithDirectOffering
3446000
CY2019Q1 us-gaap Adjustment To Additional Paid In Capital Income Tax Effect From Share Based Compensation Net
AdjustmentToAdditionalPaidInCapitalIncomeTaxEffectFromShareBasedCompensationNet
26000
CY2019Q1 us-gaap Stockholders Equity
StockholdersEquity
68626000
CY2019Q1 sndx Stock Issued During Period Value At The Market Offering Expenses
StockIssuedDuringPeriodValueAtTheMarketOfferingExpenses
34000
CY2019Q1 sndx Stock Issued During Period Value Direct Offering Common Stock Warrant
StockIssuedDuringPeriodValueDirectOfferingCommonStockWarrant
1571000
CY2020Q1 sndx Stock Issued During Period Value Offering Expenses
StockIssuedDuringPeriodValueOfferingExpenses
93000
CY2019Q1 sndx Stock Issued During Period Value Offering Expenses
StockIssuedDuringPeriodValueOfferingExpenses
78000
CY2019Q1 sndx Stock Issued During Period Value Pre Funded Common Stock Warrant
StockIssuedDuringPeriodValuePreFundedCommonStockWarrant
1875000
CY2020Q1 sndx Stock Issued During Period Value Pre Funded Common Stock Warrant Offering Expenses
StockIssuedDuringPeriodValuePreFundedCommonStockWarrantOfferingExpenses
41000
CY2019Q1 sndx Stock Issued During Period Value Pre Funded Common Stock Warrant Offering Expenses
StockIssuedDuringPeriodValuePreFundedCommonStockWarrantOfferingExpenses
93000

Files In Submission

Name View Source Status
0001564590-20-022971-index-headers.html Edgar Link pending
0001564590-20-022971-index.html Edgar Link pending
0001564590-20-022971.txt Edgar Link pending
0001564590-20-022971-xbrl.zip Edgar Link pending
FilingSummary.xml Edgar Link unprocessable
Financial_Report.xlsx Edgar Link pending
gsqqs0r5eskc000001.jpg Edgar Link pending
R1.htm Edgar Link pending
R10.htm Edgar Link pending
R11.htm Edgar Link pending
R12.htm Edgar Link pending
R13.htm Edgar Link pending
R14.htm Edgar Link pending
R15.htm Edgar Link pending
R16.htm Edgar Link pending
R17.htm Edgar Link pending
R18.htm Edgar Link pending
R19.htm Edgar Link pending
R2.htm Edgar Link pending
R20.htm Edgar Link pending
R21.htm Edgar Link pending
R22.htm Edgar Link pending
R23.htm Edgar Link pending
R24.htm Edgar Link pending
R25.htm Edgar Link pending
R26.htm Edgar Link pending
R27.htm Edgar Link pending
R28.htm Edgar Link pending
R29.htm Edgar Link pending
R3.htm Edgar Link pending
R30.htm Edgar Link pending
R31.htm Edgar Link pending
R32.htm Edgar Link pending
R33.htm Edgar Link pending
R34.htm Edgar Link pending
R35.htm Edgar Link pending
R36.htm Edgar Link pending
R37.htm Edgar Link pending
R38.htm Edgar Link pending
R39.htm Edgar Link pending
R4.htm Edgar Link pending
R40.htm Edgar Link pending
R41.htm Edgar Link pending
R42.htm Edgar Link pending
R43.htm Edgar Link pending
R44.htm Edgar Link pending
R45.htm Edgar Link pending
R46.htm Edgar Link pending
R47.htm Edgar Link pending
R48.htm Edgar Link pending
R49.htm Edgar Link pending
R5.htm Edgar Link pending
R50.htm Edgar Link pending
R6.htm Edgar Link pending
R7.htm Edgar Link pending
R8.htm Edgar Link pending
R9.htm Edgar Link pending
report.css Edgar Link pending
Show.js Edgar Link pending
sndx-10q_20200331.htm Edgar Link pending
sndx-20200331.xml Edgar Link completed
sndx-20200331.xsd Edgar Link pending
sndx-20200331_cal.xml Edgar Link unprocessable
sndx-20200331_def.xml Edgar Link unprocessable
sndx-20200331_lab.xml Edgar Link unprocessable
sndx-20200331_pre.xml Edgar Link unprocessable
sndx-ex102_933.htm Edgar Link pending
sndx-ex103_505.htm Edgar Link pending
sndx-ex104_396.htm Edgar Link pending
sndx-ex105_395.htm Edgar Link pending
sndx-ex106_394.htm Edgar Link pending
sndx-ex107_393.htm Edgar Link pending
sndx-ex311_8.htm Edgar Link pending
sndx-ex312_6.htm Edgar Link pending
sndx-ex321_7.htm Edgar Link pending